To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 504
- Registration Number
- NCT06072131
- Locations
- 🇪🇸
Hospital del Mar Medical Research Institute, Barcelona, Spain
🇪🇸Hospital Universitario y Politecnico La Fe, Valencia, Spain
🇺🇸University of California, San Francisco Fresno, Clovis, California, United States
This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT05608343
- Locations
- 🇺🇸
Nona Pediatrics, Orlando, Florida, United States
🇺🇸Tory Sullivan, MD PA, North Miami Beach, Florida, United States
🇺🇸Avant Research Associates, LLC, Crowley, Louisiana, United States
A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 542
- Registration Number
- NCT05571943
- Locations
- 🇺🇸
Qualmedica Research, LLC, Bowling Green, Kentucky, United States
🇺🇸Antelope Valley Clinical Trials, Lancaster, California, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients
- Conditions
- Interventions
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT04243434
Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
- Conditions
- Interventions
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04184869
- Locations
- 🇺🇸
John Wayne Cancer Institute @ Providence Saint John's Health Center, Santa Monica, California, United States
Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT02680795
- Locations
- 🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸John Wayne Cancer Institute @ Providence Saint John's Health Center, Santa Monica, California, United States
🇺🇸The Oncology Institute of Hope and Innovation, Whittier, California, United States
To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
- Conditions
- Interventions
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02679131
- Locations
- 🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
- Conditions
- Interventions
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02594267
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Seattle Cancer Care Alliance/University of Washington, Seattle, Washington, United States
🇺🇸MD Anderson, Houston, Texas, United States
Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02106650
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Cancer Center of Kansas, Wichita, Kansas, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
- Conditions
- Interventions
- First Posted Date
- 2013-05-10
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01851551
- Locations
- 🇺🇸
University of California, San Francisco, California, United States
🇬🇧Leeds General Infirmary, Leeds, West Yorkshire, United Kingdom